An Increased Loading Dose of Ondansetron: a North European, Double-blind Randomised Study in Children, Comparing 5 mg/m 2 with 10 mg/m 2

By Brock P.   Brichard B.   Rechnitzer C.   Langeveld N.E.   Lanning M.   Soderhall S.   Laurent C.  

European Journal of Cancer, Vol. 32, Iss. 10, 1996-09 ,pp. : 1744-1748

Elsevier

Access to resources Recommend Favorite

Therapeutic Equivalence of Single Oral Doses of Dolasetron Mesilate and Multiple Doses of Ondansetron for the Prevention of Emesis After Moderately Emetogenic Chemotherapy

By European Dolasetron Comparative Study Group   Fauser A.A.   Duclos B.   Chemaissani A.   Del Favero A.   Cognetti F.   Diaz-Rubio E.   Cortes-Funes H.   Conte P.F.   Dressler H.  

European Journal of Cancer, Vol. 32, Iss. 9, 1996-08 ,pp. : 1523-1529

Elsevier

Access to resources Recommend Favorite

Oral Ondansetron in the Prevention of Chemotherapy-induced Emesis in Breast Cancer Patients

By Clavel M.   Bonneterre J.   d'Allens H.   Paillarse J.-M.  

European Journal of Cancer, Vol. 31, Iss. 1, 1995-01 ,pp. : 15-19

Elsevier

Access to resources Recommend Favorite

Tropisetron, Ondansetron, and Granisetron for Control of Chemotherapy-Induced Emesis in Turkish Cancer Patients: A Comparison of Efficacy, Side-Effect Profile, and Cost

By Abali Huseyin   Celik Ismail  

Cancer Investigation, Vol. 25, Iss. 3, 2007-04 ,pp. : 135-139

Informa Healthcare

Access to resources Recommend Favorite

Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients

By Loos Walter   Wit Ronald   Freedman Steven   Dyck Kristien   Gambale Jay   Li Susie   Murphy Gail   Noort Connie   Bruijn Peter   Verweij Jaap  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 3, 2007-03 ,pp. : 407-412

Springer Publishing Company

Access to resources Recommend Favorite